FDA Import Alerts: One Clean Shipment Doesn’t Clear the Red List

Under FD&C Act Section 801(a), FDA can refuse admission to anything imported that merely appears to violate the Act — it does not have to prove a violation to detain a shipment. Import alerts are the mechanism that turns that authority into a standing instruction: a firm or product goes on Detention Without Physical Examination, commonly called the Red List, and every shipment is held at the border until the importer proves otherwise. The question every compliance team asks the moment they land on one is how to get off it. The answer most teams get wrong is assuming the next clean shipment settles it.

What DWPE actually requires FDA to show

FDA's Regulatory Procedures Manual is explicit that detention does not require a comprehensive examination. A brief examination is enough if it creates the appearance of a violation, and the statute allows refusal based on "examination of such samples or otherwise" — meaning FDA can rely on a pattern of prior findings, not just the shipment in front of it. That is the entire logic of an import alert: instead of re-evaluating each entry case by case, FDA shifts the burden to the importer for every future shipment once a pattern is established.

• The trigger is a pattern, not a single event. Import alerts are typically issued after FDA identifies a firm, product, or product category as not meeting GMP or other requirements across more than one instance.
• The exemption list's name varies by alert. FDA's own industry FAQ calls the list of firms exempt from DWPE the Yellow List; individual import alerts have also used the term Green List for the same concept. Check the specific alert's own terminology rather than assuming consistency across FDA's site.
• Detention is automatic once listed. A firm or product on the Red List is held at every port of entry without case-by-case evaluation, regardless of whether a given shipment has any defect at all.

Why one clean shipment changes nothing

FDA's own industry FAQ is direct about the removal standard: a firm comes off the Red List once it has demonstrated, through a documented run of consecutive non-violative shipments — five is the figure most import alerts specify, though a given alert's own text can set a different number for its product category — that the appearance of the violation has been overcome. Each of those shipments has to be a normal commercial entry, released by FDA based on acceptable private laboratory analysis. One passed inspection, or one favorable lab result, proves nothing on its own; it is one data point in a sequence FDA has defined in advance.

Removal isn't a test you pass once. It's a pattern you have to rebuild, in the same direction and with the same rigor as the pattern that got you listed in the first place. Why the shipment count exists

That design choice is deliberate, and it mirrors how FDA evaluates enforcement actions more broadly: a single data point, in either direction, is weak evidence of a systemic condition. The import alert was triggered by a pattern; FDA's removal standard asks the importer to demonstrate the opposite pattern, under the same evidentiary discipline. Treating the fifth clean shipment as a formality, rather than as the moment the evidentiary record closes, is where otherwise well-run remediation efforts stall.

The firms that get off an import alert quickly are the ones that treat the shipment count as the proof, not the project. The underlying GxP compliance work — fixing the manufacturing deviation, the labeling error, or the contamination source that triggered DWPE in the first place — has to be done and documented before the consecutive-shipment clock is worth starting. Run it in the other order, and the fifth shipment just buys a sixth detention the next time an inspector looks past the paperwork. If your team is managing an active import alert, the quality and compliance case for removal should be built once, correctly, not rebuilt after a denied petition.